Result of IXICO General Meeting

December 7, 2015

7 December 2015: IXICO plc (AIM: IXI), the brain health company, today announces that at the General Meeting held earlier today, all the resolutions proposed were unanimously passed by the requisite majorities with Resolution 2 conducted on a poll.

The full text of the resolutions can be found in the Notice of the General Meeting set out in the Circular published by the Company on 18 November 2015 (see here).

Application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 11,229,922 New Ordinary Shares comprising 8,852,459 Placing Shares, 2,357,463 Completion Consideration Shares and 20,000 Broker Option Shares which have been subscribed for under the terms of the Placing Agreement. It is expected that Admission will become effective at 8.00 a.m. on 8 December 2015.  Following Admission, the Company will have 26,445,586 Ordinary Shares in issue.

Unless otherwise defined, terms in this announcement shall have the same meanings as those defined in the shareholder circular dated 18 November 2015.

For further information, please contact:

Derek Hill, CEO

Susan Lowther, CFO

Charles Spicer, VP Corporate Development

Tel: +44 (0) 20 3763 7499

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel

Oliver Jackson

Sohail Akbar

Tel: +44 (0) 20 7418 8900

FTI Consulting Limited (Investor Relations)

Simon Conway

Mo Noonan

Matthew Moss

Tel: +44 (0) 20 3727 1000

Notes to Editors


IXICO, the brain health company, uses its innovative and proprietary digital platform technologies to help those involved in researching and treating serious diseases to make rapid, informed decisions targeted at improving patient outcomes.  IXICO has significant experience working with global pharmaceutical and biotechnology companies supporting clinical studies in the field of neuro-degenerative disorders including dementia, Alzheimer's disease, Huntington's disease and Multiple Sclerosis. 

More information is available on